Beta-3 adrenergic stimulation of L-type Ca(2+) channels in rat portal vein myocytes

Br J Pharmacol. 2000 Apr;129(7):1497-505. doi: 10.1038/sj.bjp.0703187.

Abstract

1. The effects of beta(3)-adrenergic stimulation were studied on the L-type Ca(2+) channel in single myocytes from rat portal vein using the whole-cell mode of the patch-clamp technique. 2. Reverse transcription-polymerase chain reaction showed that beta(1)-, beta(2)- and beta(3)-adrenoceptor subtypes were expressed in rat portal vein myocytes. Application of both propranolol (a non-selective beta(1)- and beta(2)-adrenoceptor antagonist) and SR59230A (a beta(3)-adrenoceptor antagonist) were needed to inhibit the isoprenaline-induced increase in L-type Ca(2+) channel current. 3. L-type Ca(2+) channels were stimulated by CGP12177A (a beta(3)-adrenoceptor agonist with potent beta(1)- and beta(2)-adrenoceptor antagonist property) in a manner similar to that of isoprenaline. The CGP12177A-induced stimulation of Ca(2+) channel current was blocked by SR59230A, cyclic AMP-dependent protein kinase inhibitors, H-89 and Rp 8-Br-cyclic AMPs, but was unaffected by protein kinase C inhibitors, GF109203X and 19-31 peptide. This stimulation was mimicked by forskolin and 8-Br-cyclic AMP. In the presence of okadaic acid (a phosphatase inhibitor), the beta(3)-adrenoceptor-induced stimulation was maintained after withdrawal of the agonist. 4. The beta(3)-adrenoceptor stimulation of L-type Ca(2+) channels was blocked by a pretreatment with cholera toxin and by the intracellular application of an anti-Galpha(s) antibody. This stimulation was unaffected by intracellular infusion of an anti-Gbeta(com) antibody and a betaARK(1) peptide. 5. These results show that activation of beta(3)-adrenoceptors stimulates L-type Ca(2+) channels in vascular myocytes through a Galpha(s)-induced stimulation of the cyclic AMP/protein kinase A pathway and the subsequent phosphorylation of the channels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Propanol / pharmacology
  • 8-Bromo Cyclic Adenosine Monophosphate / pharmacology
  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Barium / pharmacology
  • Calcium Channels, L-Type / drug effects
  • Calcium Channels, L-Type / metabolism*
  • Cells, Cultured
  • Cholera Toxin / pharmacology
  • Colforsin / pharmacology
  • Dose-Response Relationship, Drug
  • Electric Stimulation
  • Isoproterenol / pharmacology
  • Isoquinolines / pharmacology
  • Membrane Potentials / drug effects
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiology*
  • Phorbol 12,13-Dibutyrate / pharmacology
  • Portal Vein / cytology
  • Portal Vein / drug effects
  • Portal Vein / physiology*
  • Propanolamines / pharmacology
  • RNA, Messenger / genetics
  • Rats
  • Receptors, Adrenergic, beta / drug effects
  • Receptors, Adrenergic, beta / genetics
  • Receptors, Adrenergic, beta / physiology*
  • Receptors, Adrenergic, beta-3
  • Reverse Transcriptase Polymerase Chain Reaction
  • Signal Transduction
  • Sulfonamides*

Substances

  • 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate
  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Calcium Channels, L-Type
  • Isoquinolines
  • Propanolamines
  • RNA, Messenger
  • Receptors, Adrenergic, beta
  • Receptors, Adrenergic, beta-3
  • Sulfonamides
  • Colforsin
  • 8-Bromo Cyclic Adenosine Monophosphate
  • Barium
  • Phorbol 12,13-Dibutyrate
  • Cholera Toxin
  • 1-Propanol
  • Isoproterenol
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • CGP 12177